期刊文献+

人肾素转基因小鼠的建立

Studies on Transgenic Mice Harboring The Human Renin Gene
下载PDF
导出
摘要 为研究人肾素基因在体内的功能和建立其药物干预实验的动物模型 ,采用显微注射法 ,将纯化的人肾素基因导入小鼠受精卵 ,再培育成转基因小鼠 .通过DIGDNA印迹和PCR分析 ,进行转基因整合检测 .在出生的 13只子代鼠中 ,得到一只转基因阳性鼠 .整合率为 7 7% ,有效率 0 3% ,转基因已稳定传代 .RT PCR显示转基因阳性鼠的肾、心和肺组织中有肾素基因表达 ,而在肝脏与骨骼肌中则未检测到 .阳性鼠血浆肾素活性较对照鼠明显升高 ,而肾与心脏组织的肾素活性则无明显变化 . In order to determine the function of, in vivo, human rennin gene and to establish an animal model for drug inhibitory experiment of human rennin, the transgenic mice were produced via microinjection method by which the mice fertilized ova were injected with the purified human rennin gene. Assay of transgene integration was determined by DIG DNA blotting hybridization and PCR analysis. One Mouse among 13 survived mice was the positive transgenic mouse. Integration efficiency was 7.7%. Overall efficiency was 0.3%. Transgene was steadily transfered from generation to generation. The human rennin transgene was found, by RT-PCR, to be expressed in the heart, kidney, and lung of transgenic mice, but not in the liver or skeletal muscle. The mean levels of rennin activity in the plasma of the transgenic mice was also found to be significantly higher than that of the control mice. However, no significant differences were seen in the mean levels of rennin activities in the kidney and heart between transgenic and control mice. These transgenic mice will provide the opportunity to investigate the rennin gene function in circulation (or tissue) rennin angiotensin system, and may, provide an experimental model for testing human rennin inhibitors as drugs.
出处 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2002年第3期483-486,共4页 Progress In Biochemistry and Biophysics
基金 国家"八五"攻关资助项目 (85 915 0 3 11) 国家重点基础研究发展规划部分资助项目 (973 ) (G2 0 0 0 0 5 690 4)~~
关键词 逆转录-聚合酶链反应 地高辛 DNA印迹 显微注射 高血压 动物模型 人肾素 转基因小鼠 human renin transgenic mice RT-PCR DIG DNA blot microinjection
  • 相关文献

参考文献2

二级参考文献8

  • 1Su X,Wei CC,Machida N,et al.Differential expression of angiotensin converting enzyme and chymase in dogs with chronic mitral regurgitation. Journal of Molecular and Cellular Cardiology . 1999
  • 2Shiota N,Okunishi H,Takai S,Mikoshiba I,Sakonjo H,Shibata N,Miyazaki M.Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation . 1999
  • 3Lowry,DH,Rosebrough,HJ,Farr,AL.Protein measurement with Folin phenol reagent. Journal of Biological Chemistry . 1951
  • 4Iwai N,Shimoike H,Kinoshita M.Cardiac angiotensin system in the hypertrophied heart. Circulation . 1995
  • 5H Urata,A Kinoshita,KS Misono,FM Bumpus,A Husain.Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. Journal of Biological Chemistry . 1990
  • 6Dzau,V. J.Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypothesis, J. Journal of Hypertension . 1989
  • 7Fukami, H,Okunishi, H,Miyazaki, M.Chymase: its patho-physiological roles and inhibitors. Current Pharmaceutical Design . 1998
  • 8何泉,陈兰英,戴蕴平,陈永福,刘力生.MLC_2-糜酶融合基因克隆及转基因小鼠的产生[J].中国生物化学与分子生物学报,1998,14(2):144-150. 被引量:5

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部